Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma

Management of Posterior Reversible Encephalopathy Syndrome Induced by Carfilzomib in a Patient With Multiple Myeloma

(2016) Xuemei Cai et al.   JOURNAL OF CLINICAL ONCOLOGY

Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD®immunomodulatory drug pomalidomide

(2015) Deepika S. Das et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Reversible and Highly Selective Inhibitor of the Proteasomal Ubiquitin Receptor Rpn13 Is Toxic to Multiple Myeloma Cells

(2015) Darci J. Trader et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Targeting PD1–PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells

(2015) A Ray et al.   LEUKEMIA

Bortezomib-Resistant Mutant Proteasomes: Structural and Biochemical Evaluation with Carfilzomib and ONX 0914

(2015) Eva M. Huber et al.   STRUCTURE

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib

(2015) S Atrash et al.   Blood Cancer Journal

Combined autophagy and proteasome inhibition

(2014) Dan T Vogl et al.   Autophagy

Regulated protein turnover: snapshots of the proteasome in action

(2014) Sucharita Bhattacharyya et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Carfilzomib-related acute kidney injury may be prevented by N-acetyl-l-cysteine

(2014) Rimda Wanchoo et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance

(2013) Z. Tian et al.   BLOOD

A bis-Benzylidine Piperidone Targeting Proteasome Ubiquitin Receptor RPN13/ADRM1 as a Therapy for Cancer

(2013) Ravi K. Anchoori et al.   CANCER CELL

In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells

(2013) D. Chauhan et al.   CLINICAL CANCER RESEARCH

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

(2012) D. S. Siegel et al.   BLOOD

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

(2012) Ravi Vij et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance

(2012) Dharminder Chauhan et al.   CANCER CELL

Inhibition of proteasome deubiquitinating activity as a new cancer therapy

(2011) Pádraig D'Arcy et al.   NATURE MEDICINE

Enhancement of proteasome activity by a small-molecule inhibitor of USP14

(2010) Byung-Hoon Lee et al.   NATURE

Recognition and Processing of Ubiquitin-Protein Conjugates by the Proteasome

(2009) Daniel Finley   Annual Review of Biochemistry

Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target

(2009) Dharminder Chauhan et al.   CANCER CELL

Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells

(2009) Chen   ONCOLOGY REPORTS

Comprehensive analysis of 20q13 genes in ovarian cancer identifiesADRM1as amplification target

(2008) Marlena S. Fejzo et al.   GENES CHROMOSOMES & CANCER

Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression

(2008) B Carvalho et al.   GUT

Ubiquitin docking at the proteasome through a novel pleckstrin-homology domain interaction

(2008) Patrick Schreiner et al.   NATURE

Proteasome subunit Rpn13 is a novel ubiquitin receptor

(2008) Koraljka Husnjak et al.   NATURE